BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 10630643)

  • 1. The role of cyclooxygenases in inflammation, cancer, and development.
    Williams CS; Mann M; DuBois RN
    Oncogene; 1999 Dec; 18(55):7908-16. PubMed ID: 10630643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
    Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [COX-2 inhibitor and colon cancer].
    Tsujii M
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1799-805. PubMed ID: 11729471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
    Evans JF
    Am J Clin Oncol; 2003 Aug; 26(4):S62-5. PubMed ID: 12902858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
    Sanborn R; Blanke CD
    Semin Oncol; 2005 Feb; 32(1):69-75. PubMed ID: 15726508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathology of cyclooxygenase-2 in neoplasia.
    Fosslien E
    Ann Clin Lab Sci; 2000 Jan; 30(1):3-21. PubMed ID: 10678579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
    Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
    Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production.
    Johnson PM; Vogt SK; Burney MW; Muglia LJ
    Am J Physiol Endocrinol Metab; 2002 Mar; 282(3):E650-6. PubMed ID: 11832369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition.
    Xu H; Izon DJ; Loftin C; Spain LM
    Cell Immunol; 2001 Dec; 214(2):184-93. PubMed ID: 12088417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
    Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
    In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
    Lipsky PE
    J Rheumatol Suppl; 1999 Apr; 56():25-30. PubMed ID: 10225537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approach to angiogenesis inhibition based on cyclooxygenase-2.
    Masferrer J
    Cancer J; 2001; 7 Suppl 3():S144-50. PubMed ID: 11779086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of cyclo-oxygenase-2.
    Stack E; DuBois RN
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):787-800. PubMed ID: 11566041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.
    Shattuck-Brandt RL; Lamps LW; Heppner Goss KJ; DuBois RN; Matrisian LM
    Mol Carcinog; 1999 Mar; 24(3):177-87. PubMed ID: 10204802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
    Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
    Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
    Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2.
    Hartwich J; Konturek SJ; Pierzchalski P; Zuchowicz M; Konturek PC; Bielański W; Marlicz K; Starzyńska T; Ławniczak M
    Med Sci Monit; 2001; 7(6):1171-81. PubMed ID: 11687726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.